GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="center"><em>Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF)</em><br /></p> <p align="center"><em>GRI-0621 interim data readout of Phase 2a biomarker study on track for Q4 2024 and topline data on track for Q1 2025 </em></p> <p align="justify"><strong>LA JOLLA, CA, Aug. 14, 2024 (GLOBE...